{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:12:44Z","timestamp":1787501564055,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Sunitinib, a tyrosine kinase inhibitor to treat GIST and mRCC may interact with paracetamol as both undergo P450 mediated biotransformation and P-glycoprotein transport. This study evaluates the effects of sunitinib-paracetamol coadministration on liver and renal function biomarkers and liver, kidney, brain, heart and spleen histopathology. ICR male mice (n = 6 per group\/dose) were administered saline (group-A) or paracetamol 500 mg\/kg IP (group-B), or sunitinib at 25, 50, 80, 100, 140 mg\/kg PO (group-C) or coadministered sunitinib at 25, 50, 80, 100, 140 mg\/kg PO and paracetamol IP at fixed dose 500 mg\/kg (group-D). Paracetamol was administered 15 min before sunitinib. Mice were sacrificed 4 h post sunitinib administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Group-A serum ALT and AST levels were 14.29 \u00b1 2.31 U\/L and 160.37 \u00b1 24.74 U\/L respectively and increased to 249.6 \u00b1 222.7 U\/L and 377.1 \u00b1 173.6 U\/L respectively in group-B; group-C ALT and AST ranged 36.75-75.02 U\/L and 204.4-290.3 U\/L respectively. After paracetamol coadministration with low sunitinib doses (group-D), ALT and AST concentrations ranged 182.79-221.03 U\/L and 259.7-264.4 U\/L respectively, lower than group-B. Paracetamol coadministration with high sunitinib doses showed higher ALT and AST values (range 269.6-349.2 U\/L and 430.2-540.3 U\/L respectively), p &lt; 0.05. Hepatic histopathology showed vascular congestion in group-B; mild congestion in group-C (but lesser than in group-B and D). In group-D, at low doses of sunitinib, lesser damage than in group-B occurred but larger changes including congestion were observed at high sunitinib doses. BUN levels were higher (p &lt; 0.05) for group-B (33.81 \u00b1 5.68 mg\/dL) and group-D (range 35.01 \u00b1 6.95 U\/L to 52.85 \u00b1 12.53 U\/L) compared to group-A (15.60 \u00b1 2.17 mg\/dL) and group-C (range 17.50 \u00b1 1.25 U\/L to 26.68 \u00b1 6.05 U\/L). Creatinine remained unchanged. Renal congestion and necrosis was lower in group-C than group-B but was higher in group-D (p &gt; 0.05). Mild cardiotoxicity occurred in groups B, C and D. Brain vascular congestion occurred at high doses of sunitinib administered alone or with paracetamol. Hepatic and renal biomarkers correlated with histopathology signs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Paracetamol and sunitinib coadministration may lead to dose dependent outcomes exhibiting mild hepatoprotective effect or increased hepatotoxicity. Sunitinib at high doses show renal, cardiac and brain toxicity. Liver and renal function monitoring is recommended.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1471-2210-10-14","type":"journal-article","created":{"date-parts":[[2010,10,15]],"date-time":"2010-10-15T14:17:22Z","timestamp":1287152242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Histopathology and biochemistry analysis of the interaction between sunitinib and paracetamol in mice"],"prefix":"10.1186","volume":"10","author":[{"given":"Adeline YL","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Segarra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikumar","family":"Chakravarthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sufyan","family":"Akram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Judson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,10,15]]},"reference":[{"key":"727_CR1","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/nrc1887","volume":"6","author":"CD Scripture","year":"2006","unstructured":"Scripture CD, Figg WD: Drug interactions in cancer therapy. Nat Rev Cancer. 2006, 6: 546-58. 10.1038\/nrc1887.","journal-title":"Nat Rev Cancer"},{"key":"727_CR2","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1093\/annonc\/mdp369","volume":"20","author":"RP Riechelmann","year":"2009","unstructured":"Riechelmann RP, Giglio AD: Drug interactions in oncology: How common are they?. Ann Oncol. 2009, 20: 1907-1912. 10.1093\/annonc\/mdp369.","journal-title":"Ann Oncol"},{"key":"727_CR3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1093\/jnci\/djk130","volume":"99","author":"RP Riechelmann","year":"2007","unstructured":"Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK: Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007, 99: 592-600. 10.1093\/jnci\/djk130.","journal-title":"J Natl Cancer Inst"},{"key":"727_CR4","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1196\/annals.1414.033","volume":"1138","author":"PJ Christo","year":"2008","unstructured":"Christo PJ, Mazloomdoost D: Cancer pain and analgesia. Ann N Y Acad Sci. 2008, 1138: 278-98. 10.1196\/annals.1414.033.","journal-title":"Ann N Y Acad Sci"},{"key":"727_CR5","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/S0140-6736(00)04515-3","volume":"357","author":"SC Weiss","year":"2001","unstructured":"Weiss SC, Emanuel LL, Fairclough DL, Emanuel EJ: Understanding the experience of pain in terminally ill patients. The Lancet. 2001, 357: 1311-1315. 10.1016\/S0140-6736(00)04515-3.","journal-title":"The Lancet"},{"key":"727_CR6","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.3748\/wjg.v13.i48.6608","volume":"13","author":"E Ridruejo","year":"2007","unstructured":"Ridruejo E, Cacchione R, Villamil AG, Marciano S, Gadano AC, Mando OG: Imatinib-induced fatal acute liver failure. World J Gastroenterol. 2007, 13: 6608-6611.","journal-title":"World J Gastroenterol"},{"key":"727_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/0253-7613.56071","volume":"41","author":"I Nassar","year":"2009","unstructured":"Nassar I, Pasupati T, Judson JP, Segarra I: Reduced exposure of imatinib after coadministration with acetaminophen to mice. Ind J Pharmacol. 2009, 41: 167-172. 10.4103\/0253-7613.56071.","journal-title":"Ind J Pharmacol"},{"key":"727_CR8","first-page":"1","volume":"32","author":"I Nassar","year":"2010","unstructured":"Nassar I, Pasupati T, Judson JP, Segarra I: Histopathological study of the hepatic and renal toxicity associated with the coadministration of imatinib and acetaminophen in a preclinical mouse model. Malays J Path. 2010, 32: 1-11. [http:\/\/www.mjpath.org.my\/2010.1\/co-administration_Imatinib_Acetaminophen.pdf]","journal-title":"Malays J Path"},{"key":"727_CR9","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1345\/aph.1L528","volume":"43","author":"AM Weise","year":"2009","unstructured":"Weise AM, Liu CY, Shields AF: Fatal liver failure in a patient on acetaminophen treated with sunitinib malate and levothyroxine. Ann Pharmacother. 2009, 43: 761-766. 10.1345\/aph.1L528.","journal-title":"Ann Pharmacother"},{"key":"727_CR10","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","volume":"13","author":"VL Goodman","year":"2007","unstructured":"Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS, Booth BP, Verbois SL, Morse DE, Liang CY, Chidambaram N, Jiang JX, Tang S, Mahjoob K, Justice R, Pazdur R: Approval summary: Sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007, 13: 1367-1373. 10.1158\/1078-0432.CCR-06-2328.","journal-title":"Clin Cancer Res"},{"key":"727_CR11","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA: Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009, 27: 3584-3590. 10.1200\/JCO.2008.20.1293.","journal-title":"J Clin Oncol"},{"key":"727_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2146\/ajhp060661","volume":"65","author":"JJ Hiles","year":"2008","unstructured":"Hiles JJ, Kolesar JM: Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health-Syst Pharm. 2008, 65: 123-131. 10.2146\/ajhp060661.","journal-title":"Am J Health-Syst Pharm"},{"key":"727_CR13","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM, et al.: In vivo Antitumor Activity of SU11248 a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet derived Growth Factor Receptors: Determination of a Pharmacokinetic\/pharmacodynamic Relationship. Clin Cancer Res. 2003, 9: 327-337.","journal-title":"Clin Cancer Res"},{"key":"727_CR14","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","volume":"101","author":"AM O'Farrell","year":"2003","unstructured":"O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003, 101: 3597-3605. 10.1182\/blood-2002-07-2307.","journal-title":"Blood"},{"key":"727_CR15","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4161\/cbt.2.5.446","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM: SU11248 inhibits KIT and platelet derived growth factor receptor \u03b2 in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003, 2: 471-478.","journal-title":"Mol Cancer Ther"},{"key":"727_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.bbrc.2007.02.156","volume":"356","author":"R Roskoski","year":"2007","unstructured":"Roskoski R: Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 2007, 356: 323-328. 10.1016\/j.bbrc.2007.02.156.","journal-title":"Biochem Biophys Res Commun"},{"key":"727_CR17","first-page":"757","volume-title":"Clin Exp Metastasis","author":"LJ Murray","year":"2003","unstructured":"Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O'Farrell AM, Cherrington JM, Pryer NK: SU1124208 inhibits tumor growth and CSF1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis. 2003, 757-766. 10.1023\/B:CLIN.0000006873.65590.68."},{"key":"727_CR18","first-page":"25","volume-title":"J Clin Onco","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo , Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E: Safety, pharmacokinetic, and antitumor activity of SU1124248, a Novel Oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Onco. 2006, 25-35. 10.1200\/JCO.2005.02.2194."},{"key":"727_CR19","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1200\/JCO.2006.06.3602","volume":"25","author":"LQM Chow","year":"2007","unstructured":"Chow LQM, Eckhardt SG: Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007, 25: 884-896. 10.1200\/JCO.2006.06.3602.","journal-title":"J Clin Oncol"},{"key":"727_CR20","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00280-008-0917-1","volume":"64","author":"J Haznedar","year":"2008","unstructured":"Haznedar J, Patyna S, Bello CL, Peng G, Speed W, Yu XM, Zhang QL, Sukbuntherng J, Sweeny D, Antonian L, Wu E: Single and multiple dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol. 2008, 64: 691-706. 10.1007\/s00280-008-0917-1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"727_CR21","first-page":"353","volume-title":"Anti-Cancer Drugs","author":"CL Bello","year":"2006","unstructured":"Bello CL, Sherman L, Zhou J, Verkh L, Smeraglia J, Mount J, Klamerus KJ: Effect of food on the pharmacokinetics of sunitinib malate (SU1124178), a multi targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anti-Cancer Drugs. 2006, 353-358. 10.1097\/00001813-200603000-00015."},{"key":"727_CR22","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH: Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet. 2007, 370: 2011-2019. 10.1016\/S0140-6736(07)61865-0.","journal-title":"Lancet"},{"key":"727_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/jnci\/djk008","volume":"99","author":"BI Rini","year":"2007","unstructured":"Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007, 99: 81-83. 10.1093\/jnci\/djk008.","journal-title":"J Natl Cancer Inst"},{"key":"727_CR24","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","volume":"19","author":"ME Lacouture","year":"2008","unstructured":"Lacouture ME, Reilly LM, Gerami P, Guitart J: Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008, 19: 1955-1961. 10.1093\/annonc\/mdn389.","journal-title":"Ann Oncol"},{"key":"727_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00280-007-0498-4","volume":"61","author":"CD Britten","year":"2008","unstructured":"Britten CD, Kabbinavar F, Hecht JR, Bello CL, Li J, Baum C, Slamon D: A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol. 2008, 61: 515-524. 10.1007\/s00280-007-0498-4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"727_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11523-007-0050-9","volume":"2","author":"J Medioni","year":"2007","unstructured":"Medioni J, Cojocarasu O, Banu E, Queudeville AC, Halimi P, Oudard S: Reversible encephalopathy syndrome secondary to sunitinib for metastatic cell carcinoma patient. Targ Oncol. 2007, 2: 193-195. 10.1007\/s11523-007-0050-9.","journal-title":"Targ Oncol"},{"key":"727_CR27","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","volume":"368","author":"GD Demetri","year":"2006","unstructured":"Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006, 368: 1329-1338. 10.1016\/S0140-6736(06)69446-4.","journal-title":"Lancet"},{"key":"727_CR28","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(07)60903-9","volume":"369","author":"T Nicholaou","year":"2007","unstructured":"Nicholaou T, Wong R, Davis ID: Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet. 2007, 369: 1923-1924. 10.1016\/S0140-6736(07)60903-9.","journal-title":"Lancet"},{"key":"727_CR29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.ctrv.2009.08.004","volume":"35","author":"NP van Erp","year":"2009","unstructured":"van Erp NP, Gelderblom H, Guchelaar HJ: Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev. 2009, 35: 692-706. 10.1016\/j.ctrv.2009.08.004.","journal-title":"Cancer Treat Rev"},{"key":"727_CR30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/BF03160941","volume":"4","author":"M Mazer","year":"2008","unstructured":"Mazer M, Perrone J: Acetaminophen-induced nephrotoxicity: Pathophysiology, clinical manifestations, and management. J Med Toxicol. 2008, 4: 2-6. 10.1007\/BF03160941.","journal-title":"J Med Toxicol"},{"key":"727_CR31","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1365-2125.2007.02952.x","volume":"64","author":"N Pakravan","year":"2007","unstructured":"Pakravan N, Bateman DN, Godddard J: Effect of acute paracetamol overdose on changes in serum and urine electrolytes. Br J Clin Pharmacol. 2007, 64: 824-832.","journal-title":"Br J Clin Pharmacol"},{"key":"727_CR32","first-page":"369","volume-title":"Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol","author":"JA Hinson","year":"2010","unstructured":"Hinson JA, Roberts DW, James LP: Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010, 196: 369-405."},{"key":"727_CR33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/00498250802512830","volume":"39","author":"JE Laine","year":"2009","unstructured":"Laine JE, Auriola S, Pasanen M, Juvonen RO: Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica. 2009, 39: 11-21. 10.1080\/00498250802512830.","journal-title":"Xenobiotica"},{"key":"727_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1136\/pgmj.69.807.52","volume":"69","author":"A Armour","year":"1993","unstructured":"Armour A, Slater SD: Paracetamol cardiotoxicity. Postgrad Med J. 1993, 69: 52-54. 10.1136\/pgmj.69.807.52.","journal-title":"Postgrad Med J"},{"key":"727_CR35","first-page":"95","volume":"30","author":"KH Lee","year":"2008","unstructured":"Lee KH, Chen YS, Judson JP, Chakravarthi S, Sim YM, Er HM: The effect of water extracts of Euphorbia hirta on cartilage degeneration in arthritic rats. Malays J Pathol. 2008, 30: 95-102.","journal-title":"Malays J Pathol"},{"key":"727_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.etp.2007.02.009","volume":"59","author":"K Yapar","year":"2007","unstructured":"Yapar K, Kart A, Karapehlivan M, Atakisi O, Tunca R, Erginsoy S, Citil M: Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice. Exp Toxicol Pathol. 2007, 59: 121-128. 10.1016\/j.etp.2007.02.009.","journal-title":"Exp Toxicol Pathol"},{"key":"727_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1067\/mcp.2000.104736","volume":"67","author":"PT Manyike","year":"2000","unstructured":"Manyike PT, Kharasch ED, Kalhorn TF, Slattery JT: Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther. 2000, 67: 275-282. 10.1067\/mcp.2000.104736.","journal-title":"Clin Pharmacol Ther"},{"key":"727_CR38","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/cdd.2009.107","volume":"16","author":"R Franco","year":"2009","unstructured":"Franco R, Cidlowski JA: Apoptosis and glutathione: Beyond an antioxidant. Cell Death and Differ. 2009, 16: 1303-1314. 10.1038\/cdd.2009.107.","journal-title":"Cell Death and Differ"},{"key":"727_CR39","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/ijc.24767","volume":"126","author":"SS Singhal","year":"2009","unstructured":"Singhal SS, Sehrawat A, Sahu M, Singhal P, Vatsyayan R, Lelsani PCR, Yadav S, Awasthi S: RLIP76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2009, 126: 1327-1338.","journal-title":"Int J Cancer"},{"key":"727_CR40","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1248\/bpb.28.1635","volume":"28","author":"Y Shimeda","year":"2005","unstructured":"Shimeda Y, Hirotani Y, Akimoto Y, Shindou K, Ijiri Y, Nishihori T, Tanaka K: Protective effects of capsaicin against cisplatin-induced nephrotoxicity in rats. Biol Pharm Bull. 2005, 28: 1635-1638. 10.1248\/bpb.28.1635.","journal-title":"Biol Pharm Bull"},{"key":"727_CR41","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.5483\/BMBRep.2007.40.6.1039","volume":"40","author":"A Ghosh","year":"2007","unstructured":"Ghosh A, Sil PC: Anti-oxidative effect of a protein from Cajanus indicus L against acetaminophen-induced hepato-nephro toxicity. J Biochem Mol Bio. 2007, 40: 1039-1049.","journal-title":"J Biochem Mol Bio"},{"key":"727_CR42","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1177\/0960327108090276","volume":"27","author":"MW Roomi","year":"2008","unstructured":"Roomi MW, Kalinovsky T, Ivanov V, Rath M, Niedzwiecki A: A nutrient mixture prevents acetaminophen hepatic and renal toxicity in ICR mice. Hum Exp Toxicol. 2008, 27: 223-230. 10.1177\/0960327108090276.","journal-title":"Hum Exp Toxicol"},{"key":"727_CR43","first-page":"925","volume":"1","author":"S Palani","year":"2009","unstructured":"Palani S, Raja S, Kumar RP, Jayakumar S, Kumar BS: Therapeutic efficacy of Pimpinella tirupatiensis (Apiaceae) on acetaminophen induced nephrotoxicity and oxidative stress in male albino rats. Int J PharmTech Res. 2009, 1: 925-934.","journal-title":"Int J PharmTech Res"},{"key":"727_CR44","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1046\/j.1523-1755.2003.00908.x","volume":"63","author":"H Liu","year":"2003","unstructured":"Liu H, Baliga R: Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003, 63: 1687-1696. 10.1046\/j.1523-1755.2003.00908.x.","journal-title":"Kidney Int"},{"key":"727_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/sj.bjp.0703837","volume":"132","author":"LE Futter","year":"2001","unstructured":"Futter LE, al-Swayeh OA, Moore PK: A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br J Pharmacol. 2001, 132: 10-12. 10.1038\/sj.bjp.0703837.","journal-title":"Br J Pharmacol"},{"key":"727_CR46","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/clinchem\/38.10.1933","volume":"38","author":"RD Perrone","year":"1992","unstructured":"Perrone RD, Madias NE, Levey AS: Serum creatinine as an index of renal function: New insights into old concepts. Clin Chem. 1992, 38: 1933-1953.","journal-title":"Clin Chem"},{"key":"727_CR47","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1365-2125.2007.02952.x","volume":"64","author":"N Pakravan","year":"2007","unstructured":"Pakravan N, Bateman DN, Godddard J: Effect of acute paracetamol overdose on changes in serum and urine electrolytes. Br J Clin Pharmacol. 2007, 64: 824-832.","journal-title":"Br J Clin Pharmacol"},{"key":"727_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1081\/CLT-44992","volume":"43","author":"MA Von Mach","year":"2005","unstructured":"Von Mach MA, Hermanns-Clausen M, Koch I, Hengstler JG, Lauterbach M, Kaes J, Weilemann LS: Experiences of a poison centre network with renal insufficiency in acetaminophen overdose: An analysis of 17 cases. Clin Toxicol. 2005, 43: 31-37.","journal-title":"Clin Toxicol"},{"key":"727_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1248\/jhs.55.325","volume":"55","author":"T Sakuma","year":"2009","unstructured":"Sakuma T, Kawasaki Y, Jarukamjorn K, Nemoto N: Sex differences of drug metabolizing enzyme: Female predominant expression of human and mouse cytochrome P450 3A isoforms. J Health Sci. 2009, 55: 325-337. 10.1248\/jhs.55.325.","journal-title":"J Health Sci"},{"key":"727_CR50","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1124\/mol.104.007898","volume":"67","author":"J Gu","year":"2005","unstructured":"Gu J, Cui H, Behr M, Zhang L, Zhang QY, Yang W, Hinson JA, Ding X: In vivo mechanisms of tissue-selective drug toxicity: Effects of liver-specific knockout of the NADPH-cytochrome P450 reductase gene on acetaminophen toxicity in kidney, lung, and nasal mucosa. Mol Pharmacol. 2005, 67: 623-630. 10.1124\/mol.104.007898.","journal-title":"Mol Pharmacol"},{"key":"727_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","volume":"118","author":"MH Chen","year":"2008","unstructured":"Chen MH, Kerkela R, Force T: Mechanisms of cardiomyopathy associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008, 118: 84-95. 10.1161\/CIRCULATIONAHA.108.776831.","journal-title":"Circulation"},{"key":"727_CR52","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/qjmed\/90.3.161","volume":"90","author":"AL Jones","year":"1997","unstructured":"Jones AL, Prescott LF: Unusual complications of paracetamol poisoning. QJ Med. 1997, 90: 161-168.","journal-title":"QJ Med"},{"key":"727_CR53","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1136\/bmj.4.5784.430-c","volume":"4","author":"EJ Will","year":"1971","unstructured":"Will EJ, Tomkins AM: Acute myocardial necrosis in paracetamol poisoning. Br Med J. 1971, 4: 430-431. 10.1136\/bmj.4.5784.430-c.","journal-title":"Br Med J"},{"key":"727_CR54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0022-3565(25)32797-7","volume":"219","author":"LJ Fischer","year":"1981","unstructured":"Fischer LJ, Green MD, Harman AW: Levels of acetaminophen and its metabolites in mouse tissues after a toxic dose. J Pharmacol Exp Ther. 1981, 219: 281-286.","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 1","key":"727_CR55","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S1359-6349(06)70062-3","volume":"4","author":"S Patyna","year":"2006","unstructured":"Patyna S, Peng G: Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer. 2006, 4 (Suppl 1): 21-","journal-title":"Eur J Cancer"},{"key":"727_CR56","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1093\/annonc\/mdm455","volume":"18","author":"AAM van der Veldt","year":"2007","unstructured":"van der Veldt AAM, van den Eertwegh AJM, Hoekman K, Barkhof F, Boven E: Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. Ann Oncol. 2007, 18: 1747-1750. 10.1093\/annonc\/mdm455.","journal-title":"Ann Oncol"},{"key":"727_CR57","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.mvr.2009.02.002","volume":"77","author":"D Tripathy","year":"2009","unstructured":"Tripathy D, Grammas P: Acetaminophen protects brain endothelial cells against oxidative stress. Microvascular Res. 2009, 77: 289-296. 10.1016\/j.mvr.2009.02.002.","journal-title":"Microvascular Res"},{"key":"727_CR58","volume-title":"BPharm thesis","author":"TW Koo","year":"2009","unstructured":"Koo TW: Effects of paracetamol on the pharmacokinetics and tissue disposition profiles of sunitinib after single oral dose coadministration in male mice. BPharm thesis. 2009, International Medical University, Department of Pharmaceutical Technology, Kuala Lumpur"},{"key":"727_CR59","volume-title":"BPharm thesis","author":"MH Liew","year":"2009","unstructured":"Liew MH: Effects of paracetamol on the pharmacokinetics and tissue distribution profiles of sunitinib after single oral dose coadministration to female ICR mice. BPharm thesis. 2009, International Medical University, Department of Pharmaceutical Technology, Kuala Lumpur"},{"key":"727_CR60","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1111\/j.1740-8261.2004.04039.x","volume":"45","author":"RT O'Brien","year":"2004","unstructured":"O'Brien RT, Walker KR, Osgood TL: Sonographic features of drug-induced splenic congestion. Vet Radiol Ultrasound. 2004, 45: 225-227. 10.1111\/j.1740-8261.2004.04039.x.","journal-title":"Vet Radiol Ultrasound"},{"key":"727_CR61","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.2174\/1381612043383467","volume":"10","author":"OP Medina","year":"2004","unstructured":"Medina OP, Zhu Y, Kairemo K: Targeted liposomal drug delivery in cancer. Curr Pharm Des. 2004, 10: 2981-2989. 10.2174\/1381612043383467.","journal-title":"Curr Pharm Des"},{"key":"727_CR62","first-page":"901","volume":"45","author":"KS Moo","year":"2010","unstructured":"Moo KS, Teoh M, Radhakrishnan S, Narayanan P, Bukhari NI, Segarra I: Disposition and tissue distribution of imatinib after intravenous bolus dose to mice in a liposome formulation. Acta Pharm Sinica. 2010, 45: 901-908.","journal-title":"Acta Pharm Sinica"}],"container-title":["BMC Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2210-10-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T15:30:40Z","timestamp":1740583840000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/1471-2210-10-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,15]]},"references-count":62,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["727"],"URL":"https:\/\/doi.org\/10.1186\/1471-2210-10-14","relation":{},"ISSN":["1471-2210"],"issn-type":[{"value":"1471-2210","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,15]]},"assertion":[{"value":"5 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}